PA8593701A1 - [4- (3-AMINOMETILPHENYL) PIPERIDIN-1-IL] - [5- (2-FLUOROPHENYL-ETINYL) FURAN-2-IL] -METANOMA AS A MASTOCYT TRIPTASE INHIBITOR - Google Patents

[4- (3-AMINOMETILPHENYL) PIPERIDIN-1-IL] - [5- (2-FLUOROPHENYL-ETINYL) FURAN-2-IL] -METANOMA AS A MASTOCYT TRIPTASE INHIBITOR

Info

Publication number
PA8593701A1
PA8593701A1 PA20038593701A PA8593701A PA8593701A1 PA 8593701 A1 PA8593701 A1 PA 8593701A1 PA 20038593701 A PA20038593701 A PA 20038593701A PA 8593701 A PA8593701 A PA 8593701A PA 8593701 A1 PA8593701 A1 PA 8593701A1
Authority
PA
Panama
Prior art keywords
triptase
inhibitor
metanoma
mastocyt
aminometilphenyl
Prior art date
Application number
PA20038593701A
Other languages
Spanish (es)
Inventor
Heinz W Pauls
Suzanne Aldous
Gregory H Merriman
Robert A Farr
Adam W Sledeski
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of PA8593701A1 publication Critical patent/PA8593701A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

LA PRESENTE INVENCION SE EXTIENDE AL COMPUESTO DE FORMULA (I): O UN PROFARMACO, SAL FARMACEUTICAMENTE ACEPTABLE, O SOLVATO DE DICHO COMPUESTO; A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UNA CANTIDAD FARMACEUTICAMENTE EFECTIVA DEL COMPUESTO DE FORMULA (I), Y UN VEHICULO FARMACEUTICAMENTE ACEPTABLE; AL USO DE UN COMPUESTO DE FORMULA (I) COMO UN INHIBIDOR DE TRIPTASA, QUE COMPRENDE INTRODUCIR EL COMPUESTO EN UNA COMPOSICION QUE COMPRENDE TRIPTASA.THE PRESENT INVENTION EXTENDS TO THE FORMULA COMPOUND (I): OR A PROFARMACO, PHARMACEUTICALLY ACCEPTABLE SALT, OR SOLVATE OF SUCH COMPOUND; TO A PHARMACEUTICAL COMPOSITION THAT INCLUDES A PHARMACEUTICALLY EFFECTIVE AMOUNT OF THE FORMULA COMPOUND (I), AND A PHARMACEUTICALLY ACCEPTABLE VEHICLE; TO THE USE OF A FORMULA COMPOUND (I) AS A TRIPTASE INHIBITOR, WHICH INCLUDES INTRODUCING THE COMPOUND IN A COMPOSITION THAT INCLUDES TRIPTASE.

PA20038593701A 2002-12-26 2003-12-23 [4- (3-AMINOMETILPHENYL) PIPERIDIN-1-IL] - [5- (2-FLUOROPHENYL-ETINYL) FURAN-2-IL] -METANOMA AS A MASTOCYT TRIPTASE INHIBITOR PA8593701A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43653402P 2002-12-26 2002-12-26

Publications (1)

Publication Number Publication Date
PA8593701A1 true PA8593701A1 (en) 2005-05-24

Family

ID=23732791

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20038593701A PA8593701A1 (en) 2002-12-26 2003-12-23 [4- (3-AMINOMETILPHENYL) PIPERIDIN-1-IL] - [5- (2-FLUOROPHENYL-ETINYL) FURAN-2-IL] -METANOMA AS A MASTOCYT TRIPTASE INHIBITOR

Country Status (9)

Country Link
US (1) US20040192734A1 (en)
AR (1) AR042674A1 (en)
AU (1) AU2003301137A1 (en)
GB (1) GB0308613D0 (en)
PA (1) PA8593701A1 (en)
PE (1) PE20040931A1 (en)
TW (1) TW200508227A (en)
UY (1) UY28152A1 (en)
WO (1) WO2004060884A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1571150A1 (en) * 2004-03-02 2005-09-07 Aventis Pharma Deutschland GmbH Process for the preparation of tryptase inhibitors
WO2006044133A1 (en) * 2004-09-24 2006-04-27 Axys Pharmaceuticals, Inc. Active ketone inhibitors of tryptase
JP2011504499A (en) 2007-11-21 2011-02-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Spiropiperidine for use as a tryptase inhibitor
CN111568894B (en) * 2020-05-18 2021-07-27 中国医学科学院肿瘤医院 Use of 2- (ethylaminomethyl) -5- (phenyl) furan for the preparation of a medicament for inhibiting TLR7/8

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2409827C (en) * 2000-05-22 2010-06-01 Aventis Pharmaceuticals Products Inc. Arylmethylamine derivatives for use as tryptase inhibitors

Also Published As

Publication number Publication date
AU2003301137A1 (en) 2004-07-29
UY28152A1 (en) 2004-07-30
TW200508227A (en) 2005-03-01
AR042674A1 (en) 2005-06-29
GB0308613D0 (en) 2003-05-21
US20040192734A1 (en) 2004-09-30
PE20040931A1 (en) 2004-12-24
WO2004060884A1 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
AR049274A1 (en) ACID2 - {[2- (2-METHYLAMINOPIRIMIDIN-4-IL) -1H-INDOL-5-CARBONYL] AMINO} -3- (PHENYLPIRIDIN-2-ILAMINO) SUBSTANTIALLY PURE PROPIONIC AS A SELECTIVE KINASE IKK-2 INHIBITOR
PA8591701A1 (en) PIRROLOPIRIMIDINE DERIVATIVES
SV2009003281A (en) ESPIRO KETONA ACETIL-COA CARBOXILASA.0 INHIBITORS.
AR072261A1 (en) PIPERAZIN-PIRAZOLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEMSELVES AND USES OF THE SAME AS ANTICANCERIGEN AGENTS.
GT200600134A (en) NEW COMPOUNDS OF AMINOSULPHONYL DERIVATIVES
AR047076A1 (en) PIRROLOTRIAZINE COMPOUNDS AS THYROSINE KINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS
RS52110B (en) Dipeptidyl peptidase inhibitors for treating diabetes
UY30440A1 (en) NEW COMPOUNDS
BRPI0518993A2 (en) compound or a pharmaceutically acceptable salt, solvate or ester thereof, pharmaceutical composition, and use of a compound
AR048336A1 (en) HYDROCLORIDE OF (4- (5-AMINOMETIL-2-FLUORO-PHENYL) -PIPERIDIN-1-IL) - (4-BROMO-3-METHYL-5-PROPOXI-TIOFEN-2-IL) -METANONE AS AN INHIBITOR OF THE MASTOCYT TRIPTASE
CR10027A (en) NEW DERIVATIVES OF FUSIONATED PIRROL
ECSP10010556A (en) PIRIDINES AND PIRAZINAS AS PI3K INHIBITORS
TW200626558A (en) Indazolone derivatives
ECSP088974A (en) IMIDAZOL PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE SYNTHEOSE QUINASA GLYCOGEN (GSK3)
UA94606C2 (en) 2-thioxanthine derivatives, composition containing the compound and the use thereof in therapy
CR9219A (en) TRIAZOL DERIVATIVES REPLACED AS AN OXITOCINE ANTAGONISTS
ECSP045307A (en) COMBINATION OF ORGANIC COMPOUNDS
BRPI0617655A2 (en) compound or a pharmaceutically acceptable salt thereof, or an optical isomer thereof, use of a compound, and pharmaceutical formulation
UY28979A1 (en) DERIVATIVES OF 3-CARBOXAMIDE HYDROCLORURES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCEDURE AND ITS USE, USED AS SELECTED INHIBITORS OF GSK3
BRPI0408353A (en) compound, pharmaceutical composition, methods for the treatment of susceptible neoplasms and for the treatment of viral infections, and, use of a compound
DE60333746D1 (en) thienyl compounds
UY29169A1 (en) DERIVATIVES OF 2-AMIDO-4 FENILTIAZOL, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
MX2010001020A (en) Organic compounds.
BRPI0714885B8 (en) therapeutic compounds and their use
PA8561501A1 (en) LACTAMAS AS TAQUIQUININE ANTAGONISTS